After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Dyne Therapeutics Inc is $1.39B. A total of 2.37 million shares were traded on the day, compared to an average of 1.93M shares.
In the most recent transaction, Friedl-Naderer Johanna sold 143 shares of DYN for 12.12 per share on Mar 13 ’25. After the transaction, the Chief Commercial Officer now owns 96,057 company shares. In a previous transaction on Mar 11 ’25, Scalzo Richard William sold 1,343 shares at 11.38 per share. DYN shares that SVP, Head of Finance & Admin. owns now total 122,330.
Among the insiders who sold shares, Beskrovnaya Oxana disposed of 2,153 shares on Mar 11 ’25 at a per-share price of $11.38. This resulted in the Chief Scientific Officer holding 195,840 shares of DYN after the transaction. In another insider transaction, Beskrovnaya Oxana bought 2,153 shares at $11.38 per share on Mar 11 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, DYN has a high of $47.45 and a low of $11.18.
As of this writing, DYN has an earnings estimate of -$0.83 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.52 per share and a lower estimate of -$1.07.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DYN’s latest balance sheet shows that the firm has $376.57M in Cash & Short Term Investments as of fiscal 2021. There were $32.64M in debt and $28.72M in liabilities at the time. Its Book Value Per Share was $6.16, while its Total Shareholder’s Equity was $368.20M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DYN is Buy with a score of 4.79.
